ETIDIOH - NEW

  Summary Background Chikungunya outbreaks have recurred in Brazil since 2014 . Building on earlier 28-day post-vaccination data , we now report 12-month safety and immunogenicity results of the VLA1553 vaccine in Brazilian adolescents. Methods In this double-blind, randomised, placebo-controlled, phase 3 trial , generally healthy adolescents aged 12–17 years were recruited at ten sites across Brazil. Individuals were excluded for immune-mediated or chronic arthritis or arthralgia, who are are immunologically compromised, or any recent live vaccines. Random allocation via simple block randomisation in a 2:1 ratio was stratified by baseline IgG and IgM serostatus by ELISA to receive a single intramuscular dose of VLA1553 or placebo . Assessed in the per-protocol population 28 days after vaccination, the primary endpoint was the proportion of baseline seronegative participants with chikungunya virus neutralising antibody levels assessed by a serum dilution achieving a 50% plaque redu...

  Summary Background The first chikungunya virus (CHIKV) vaccine is now licensed in Brazil, the country that reports the most cases of CHIKV globally ; however, the optimal use of the vaccine remains unclear owing to a poor understanding of CHIKV epidemiology and population immunity . We aimed to combine the distribution of cases and deaths reported since 2014 with seroprevalence studies to inform mathematical models that estimate the underlying rates of infection by state and year, and the underlying patterns of disease and death by age and sex. Methods We quantified the annual CHIKV infection and disease burden between 2014 and 2024 in each of the 27 federative units of Brazil using a mathematical model in a Bayesian framework that integrated serological surveys (n=12) and confirmed CHIKV disease cases (n=488 234) and CHIKV deaths (n=1719) reported between January, 2014, and September, 2024. Using this base, we estimated the potential impact of a vaccine over the period 2025–29 h...

  ALBANY, N.Y. (October 14, 2025) — The New York State Department of Health today announced that a case of locally acquired chikungunya has been confirmed in New York State . Laboratory testing at the Department's Wadsworth Center confirmed the case in Nassau County on Long Island . This marks the first locally acquired case of chikungunya reported in New York State . No locally acquired cases have been reported in the U.S. states and territories since 2019. An investigation suggests that the individual likely contracted the virus following a bite from an infected mosquito . While the case is classified as locally acquired based on current information, the precise source of exposure is not known. The Aedes albopictus mosquito , known to transmit chikungunya, is present in parts of downstate New York. Local transmission can occur when an A. albopictus mosquito bites an infected traveler, becomes infected and bites another person. The disease cannot be spread directly from one person...

  Abstract In July 2025, China witnessed its most significant chikungunya virus (CHIKV) outbreak since 2010. As of August 1, with over 6,000 cases reported in Foshan city, Guangdong Province . Although the clinical manifestations have been relatively mild , the rapid transmission within communities warrants our attention. In this context, we emphasize our current knowledge and the necessary actions to take. Specifically, we identify critical gaps in CHIKV control efforts and assess the effectiveness of current measures. These include vector management strategies , viral genomic surveillance , the deployment of newly approved vaccines , and the development of antiviral agents . Overall, to effectively control the epidemic of CHIKV, we require a comprehensive and multifaceted strategy for its prevention and management. Source: PLoS Pathogens,  https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1013556 ____

  Situation at a glance In 2025, a resurgence of chikungunya virus (CHIKV) disease was noted in a number of countries , including some that had not reported substantial case numbers in recent years.  Between 1 January and 30 September 2025, a total of 445 271 suspected and confirmed CHIKV disease cases and 155 deaths were reported globally from 40 countries , including autochthonous and travel imported cases.  Some WHO Regions are experiencing significant increases in case numbers compared to 2024, although others are currently reporting lower case numbers.  This uneven distribution of cases across regions makes it challenging to characterize the situation as a global rise, however, given the ongoing outbreaks reported globally in 2025, the potential for further spread remains significant .  CHIKV disease can be introduced into new areas by infected travelers and local transmission may be established if there is the presence of Aedes mosquito and a susceptible p...

  Highlights •  Most vector-borne viruses like alphaviruses are not included in routine diagnostics •  Lack of testing results in misdiagnoses and underdetection •  A new multiplexed real-time PCR assay detects all human pathogenic alphaviruses •  The new multiplex assay is more sensitive than available tests and highly specific •  The multiplex test can be applied broadly for diagnostics and molecular surveillance Abstract Background Knowledge of epidemiology, pathogenesis, and public health burden is scarce for many arthropod-borne viruses (arboviruses). Insufficient knowledge is partly due to lack of exhaustive laboratory diagnostics due to resource limitations . Among arboviruses , arthritogenic and encephalitogenic alphaviruses are globally widespread, can cause severe disease, and can co-occur regionally. Objectives We developed and validated a multiplexed real-time reverse transcription-PCR assay for the detection of all alphaviruses commonly causing...

  Abstract Climate change is increasingly recognized as a major driver of emerging infectious diseases, particularly vector-borne diseases (VBDs), which are expanding in range and intensity worldwide. Europe , traditionally considered low-risk for many arboviral infections , is now experiencing autochthonous transmission of pathogens such as dengue, chikungunya, Zika virus, West Nile virus, malaria, and leishmaniasis . Rising temperatures , altered precipitation patterns , and milder winters have facilitated the establishment and spread of competent vectors , including Aedes, Anopheles, Phlebotomus, and Culex species , in previously non-endemic areas. These climatic shifts not only impact vector survival and distribution but also influence vector competence and pathogen development , ultimately increasing transmission potential. This narrative review explores the complex relationship between climate change and VBDs, with a particular focus on pediatric populations . It highlights h...

Abstract We performed serologic surveillance for selected arthropod-borne viruses (arboviruses) in bats and opossums in the Lacandona Rainforest, Chiapas, Mexico , in 2023–2024. Sera were collected from 94 bats of at least 15 species and 43 opossums of three species. The sera were assayed by the plaque reduction neutralization test (PRNT) for antibodies to eight orthoflaviviruses ( dengue viruses 1–4, St. Louis encephalitis virus , T’Ho virus, West Nile virus, and Zika virus ) and one alphavirus (chikungunya virus; CHIKV). Twelve (12.8%) bats and 15 (34.9%) opossums contained orthoflavivirus-specific antibodies . One bat (a Jamaican fruit bat) was seropositive for Zika virus , and 11 bats contained antibodies to an undetermined orthoflavivirus , as did the 15 opossums. All bats and most opossums seropositive for an undetermined orthoflavivirus had low PRNT titers, possibly because they had been infected with another (perhaps unrecognized) orthoflavivirus not included in the PRNTs. Anti...

Summary Background Adults older than 65 years are at increased risk for atypical presentations of chikungunya disease, as well as for severe outcomes including death. Methods In this phase 3, randomised, double-blind, placebo-controlled, parallel-group trial, adults aged 65 years and older received a single intramuscular dose of Vimkunya (previously chikungunya virus virus-like particle vaccine) or placebo at ten sites in the USA. Participants, clinical site personnel, and the sponsor were masked to individual treatment assignments until all participants had completed their involvement in the trial and the database was cleaned and locked. Baseline and postvaccination chikungunya virus serum neutralising antibody (SNA) titres (NT80) were assessed at selected timepoints. Safety was assessed up to 183 days after dose administration in all participants from the exposed population who provided safety assessment data. This trial is registered with ClinicalTrials.gov, NCT05349617, and is comp...